Boehringer Ingelheim, a Germany-based pharmaceutical company, is collaborating with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases, it was reported yesterday.
Scientists will work with immune modulation in the Boehringer Ingelheim-Tsinghua University Joint Research Centre for Immuno-Infection to combat infectious diseases.
This collaboration is an initiative of Boehringer Ingelheim's Research Beyond Borders and Cancer Immunology and Immune Modulation Research Departments.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy